Literature DB >> 10638961

Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.

N Durany1, J Joseph, O M Jimenez, F Climent, P L Fernández, F Rivera, J Carreras.   

Abstract

We have compared the levels of phosphoglycerate mutase (EC 5.4.2.1), 2,3-bisphosphoglycerate phosphatase (EC 3.1.3.13), creatine kinase (EC 2.7.3.2) and enolase (EC 4.2.1.11) activities and the distribution of their isoenzymes in normal breast tissue and in breast carcinoma. Tumour tissue had higher phosphoglycerate mutase and enolase activity than normal tissue. Creatine kinase activity was higher in seven out of 12 tumours. In contrast 2,3-bisphosphoglycerate phosphatase activity was lower. Phosphoglycerate mutase, enolase and 2,3-bisphosphoglycerate phosphatase presented greater changes in the oestrogen receptor-negative/progesterone receptor-negative breast carcinomas than in the steroid receptor-positive tumours. Determined by electrophoresis, type BB phosphoglycerate mutase, type BB creatine kinase and alpha alpha-enolase were the major isoenzymes detected in normal breast tissue. Types alpha gamma and gamma gamma enolase, types MB and MM phosphoglycerate mutase were detected in much lower proportions. In tumours a decrease of phosphoglycerate mutase isoenzymes possessing M-type subunit and some increase of enolase isoenzymes possessing gamma-type subunit was observed. No detectable change was observed in the creatine kinase phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638961      PMCID: PMC2363199          DOI: 10.1054/bjoc.1999.0871

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  67 in total

1.  Stability and electrophoretic characteristics of creatine kinase BB extracted from human brain and intestine.

Authors:  S L Chastain; C H Ketchum; W E Grizzle
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

Review 2.  Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells.

Authors:  P J Marangos; D E Schmechel
Journal:  Annu Rev Neurosci       Date:  1987       Impact factor: 12.449

Review 3.  Heterogeneity in hormone receptor status in primary and metastatic breast cancer.

Authors:  C K Osborne
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

4.  Enolase isoenzymes as diagnostic markers.

Authors:  J A Royds; C B Taylor; W R Timperley
Journal:  Neuropathol Appl Neurobiol       Date:  1985 Jan-Feb       Impact factor: 8.090

5.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

6.  Heterogeneity of estrogen binding sites in breast cancer: morphologic demonstration and relationship to endocrine response.

Authors:  L P Pertschuk; K B Eisenberg; A C Carter; J G Feldman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Breast carcinomas with neuroendocrine differentiation.

Authors:  J M Nesland; V A Memoli; R Holm; V E Gould; J V Johannessen
Journal:  Ultrastruct Pathol       Date:  1985       Impact factor: 1.094

8.  Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues.

Authors:  H Haimoto; Y Takahashi; T Koshikawa; H Nagura; K Kato
Journal:  Lab Invest       Date:  1985-03       Impact factor: 5.662

Review 9.  Bisphosphorylated metabolites of glycerate, glucose, and fructose: functions, metabolism and molecular pathology.

Authors:  J Carreras; R Bartrons; F Climent; R Cusso
Journal:  Clin Biochem       Date:  1986-12       Impact factor: 3.281

10.  Neuron-specific enolase expression and neuroendocrine differentiation in carcinomas of the breast.

Authors:  E Wilander; S Påhlman; J Sällström; A Lindgren
Journal:  Arch Pathol Lab Med       Date:  1987-09       Impact factor: 5.534

View more
  21 in total

1.  A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24.

Authors:  Kathryn S Higginbotham; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Peggy A Schuyler; W Dale Plummer; Marcia E Freudenthal; Amy Trentham-Dietz; Polly A Newcomb; Fritz F Parl; Melinda E Sanders; David L Page; Kathleen M Egan; William D Dupont; Jeffrey R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-17       Impact factor: 4.254

2.  Proteomic analyses of gastric cancer cells treated with vesicular stomatitis virus matrix protein.

Authors:  Dequan Zeng; Tao Zhang; Shengtao Zhou; Hao Hu; Jingyi Li; Kai Huang; Yunlong Lei; Kui Wang; Yong Zhao; Rui Liu; Qiu Li; Yanjun Wen; Canhua Huang
Journal:  Protein J       Date:  2011-06       Impact factor: 2.371

3.  Phosphoglycerate Mutase 1 Promotes Cell Proliferation and Neuroblast Differentiation in the Dentate Gyrus by Facilitating the Phosphorylation of cAMP Response Element-Binding Protein.

Authors:  Hyo Young Jung; Hyun Jung Kwon; Woosuk Kim; Sung Min Nam; Jong Whi Kim; Kyu Ri Hahn; Dae Young Yoo; Moo-Ho Won; Yeo Sung Yoon; Dae Won Kim; In Koo Hwang
Journal:  Neurochem Res       Date:  2018-11-20       Impact factor: 3.996

4.  Comparative proteome analysis of breast cancer and normal breast.

Authors:  Yuanming Luo; Jindan Zhang; Yanxin Liu; Allan Christian Shaw; Xiaorong Wang; Shuzhen Wu; Xuan Zeng; Jie Chen; Youhe Gao; Dexian Zheng
Journal:  Mol Biotechnol       Date:  2005-03       Impact factor: 2.695

5.  Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase.

Authors:  Yanping Xu; Fulong Li; Lei Lv; Tingting Li; Xin Zhou; Chu-Xia Deng; Kun-Liang Guan; Qun-Ying Lei; Yue Xiong
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

Review 6.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

7.  Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity.

Authors:  D Zhang; N Jin; W Sun; X Li; B Liu; Z Xie; J Qu; J Xu; X Yang; Y Su; S Tang; H Han; D Chen; J Ding; M Tan; M Huang; M Geng
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

8.  Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.

Authors:  Fenglian Ren; Hong Wu; Yunlong Lei; Haiyuan Zhang; Rui Liu; Yong Zhao; Xiancheng Chen; Dequan Zeng; Aiping Tong; Lijuan Chen; Yuquan Wei; Canhua Huang
Journal:  Mol Cancer       Date:  2010-04-19       Impact factor: 27.401

Review 9.  Emerging metabolic targets in cancer therapy.

Authors:  Yuhua Zhao; Hao Liu; Adam I Riker; Oystein Fodstad; Susan P Ledoux; Glenn L Wilson; Ming Tan
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

10.  Low serum creatine kinase levels in breast cancer patients: a case-control study.

Authors:  Hong Pan; Kai Xia; Wenbin Zhou; Jinqiu Xue; Xiuqing Liang; Lin Cheng; Naping Wu; Mengdi Liang; Dan Wu; Lijun Ling; Qiang Ding; Lin Chen; Xiaoming Zha; Xiaoan Liu; Shui Wang
Journal:  PLoS One       Date:  2013-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.